Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy (RECORA)

Bayer

Status: Completed

Conditions: Colorectal Neoplasm

Treatments: Drug: Regorafenib (Stivarga, BAY 73-4506)

Study type: Observational

Funder types: Industry

Identifiers

NCT01959269

16665

SV1313 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely observational, only data from routine treatment are to be collected. The treatment and treatment conditions are solely at discretion of the treating physician.

Enrollment: 483 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:´

• Male or female patients ≥ 18 years of age with metastatic CRC for whom the decision has been taken by the investigator to treat with Stivarga.
• Patients must have signed an informed consent form

Exclusion Criteria:

Trial design

483 participants in 1 patient group

Regorafenib

Description:

Patients treated with Stivarga as 3rd or 4th line treatment, no intervention

Treatment:

Drug: Regorafenib (Stivarga, BAY 73-4506)